WO2023036219A1 - 低聚半乳糖醛酸多糖、复合物及其制备方法和应用 - Google Patents

低聚半乳糖醛酸多糖、复合物及其制备方法和应用 Download PDF

Info

Publication number
WO2023036219A1
WO2023036219A1 PCT/CN2022/117713 CN2022117713W WO2023036219A1 WO 2023036219 A1 WO2023036219 A1 WO 2023036219A1 CN 2022117713 W CN2022117713 W CN 2022117713W WO 2023036219 A1 WO2023036219 A1 WO 2023036219A1
Authority
WO
WIPO (PCT)
Prior art keywords
parts
treatment
galacturonic acid
weight
acid polysaccharide
Prior art date
Application number
PCT/CN2022/117713
Other languages
English (en)
French (fr)
Inventor
沈彦伟
俞露
Original Assignee
上海见杉医学技术有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海见杉医学技术有限公司 filed Critical 上海见杉医学技术有限公司
Priority to JP2023544454A priority Critical patent/JP2024505861A/ja
Publication of WO2023036219A1 publication Critical patent/WO2023036219A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0045—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Galacturonans, e.g. methyl ester of (alpha-1,4)-linked D-galacturonic acid units, i.e. pectin, or hydrolysis product of methyl ester of alpha-1,4-linked D-galacturonic acid units, i.e. pectinic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A61K36/725—Ziziphus, e.g. jujube
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734—Crataegus (hawthorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the invention relates to the field of polysaccharides, in particular to oligogalacturonic acid polysaccharides, complexes, preparation methods and applications thereof.
  • HG Homogalacturonan
  • MCP modified citrus pectin
  • MCP modified citrus pectin
  • Gum polysaccharides are hydrolyzed and lipid-lowering, and the fibers with smaller molecular weight and unbranched chains have uniform chemical composition, are easy to dissolve, and are easy to absorb when taken orally.
  • LCP Small-molecule citrus pectin
  • U.S. Santley Company following the "modified pectin" made from orange peel. It is a mixture with unstable chemical composition. Its molecular weight ranges from 10kDa to 20kDa, the degree of esterification ranges from 10% to 25%.
  • Small molecule citrus pectin LCP is a mixture of various polysaccharides, including rhamngalacturonan I (RGI), rhamngalacturonan II (RGII), galacturonic acid Glycans (Homogalacturonan, HG) and xylogalacturonan (XG), arabinan, arabinogalacturonan I and arabinogalacturonan II and other sugar chains.
  • rhamngalacturonan I rhamngalacturonan I
  • RKIII rhamngalacturonan II
  • XG xylogalacturonan
  • Galectin-3 can directly mediate the aggregation among tumor cells in blood, and the recognition and adhesion between tumor cells and matrix. It has been confirmed that a variety of highly metastatic tumor cells can express Galectin-3 at high levels, and high expression of Galectin-3 can be detected in both primary tumors and metastatic tumor lesions, and its increased expression is positively correlated with tumor growth and metastasis , can be used as a differential diagnosis of certain tumor malignancies. Therefore, it is generally believed that the purpose of treating and controlling cancer metastasis can be achieved by blocking or blocking the adhesion and aggregation mediated by Galectin-3.
  • MCP is a high-affinity ligand of Galectin-3, which has a competitive inhibitory effect on Galectin-3 ligands in vivo.
  • Platt et al. (Platt D et al., Modulation of the lung colonization of B16-F1 melanoma cells by citrus pectin[J]. JNCI Cancer Spectrum, 1992,84(6):438) confirmed by in vitro cell agglutination and cell adhesion experiments , MCP can inhibit the mutual recognition and adhesion between cells by blocking Galectin-3 on the cell surface. When MCP reaches a certain concentration, Galectin-3 on the surface of tumor cells is almost blocked by MCP binding, thereby blocking mutual recognition and aggregation between cells. Some animal experiments have confirmed that MCP can effectively inhibit tumor growth and metastasis.
  • the purpose of the present invention is to provide the application of galacturonic acid polysaccharide as medicine, food or health care product: to eliminate Galectin-3-related MDSC cell differentiation and aggregation, and the downstream T cells and neutrophil ratio changes and Altered function, and the resulting systemic oxidative stress, chronic inflammation, free radical damage, and progeria.
  • galacturonic acid polysaccharide as medicine, food or health care product: to eliminate Galectin-3-related MDSC cell differentiation and aggregation, and the downstream T cells and neutrophil ratio changes and Altered function, and the resulting systemic oxidative stress, chronic inflammation, free radical damage, and progeria.
  • Its chemical structural formula is as follows:
  • the inventors of the present invention found that the compound HG can antagonize the in vitro proliferation of MDSC cells by antagonizing the ligand Galectin-3 on the surface of MDSC cells, and inhibit the spleen aggregation of MDSC in vivo, so as to realize the effect on oxidative stress, chronic inflammation, Free radical damage and control of premature diseases.
  • the compound itself has no obvious toxic and side effects on the body when used alone.
  • galacturonic acid polysaccharide can nourish intestinal probiotics and assist in regulating sugar and lipid metabolism. There is no report on galacturonic acid polysaccharide and its derivatives in the existing literature search.
  • the purpose of the present invention is to provide a galacturonic acid polysaccharide with anti-inflammatory effect and its preparation method and application, so as to solve the above problems.
  • the invention provides a kind of preparation method of oligogalacturonic acid polysaccharide, and described preparation method comprises the following steps:
  • the pore size of the ultrafiltration membrane is 1-10nm, maintain a low pressure difference of 0.05-0.5MPa for continuous high-flow extraction, and the molecular weight cut-off is 10 3 -10 4 ;
  • the invention provides a galacturonic acid polysaccharide complex, which comprises in parts by weight:
  • the molecular weight of the oligogalacturonic acid polysaccharide is 3kDa to 7kDa, and the degree of esterification is 5%-15%.
  • the galacturonic acid polysaccharide complex in parts by weight, comprises:
  • the molecular weight of the oligogalacturonic acid polysaccharide is 3kDa to 7kDa, and the degree of esterification is 5%-15%.
  • the present invention provides a polygalacturonic acid polysaccharide complex, in parts by weight, comprising:
  • the galacturonic acid in the oligogalacturonic acid polysaccharide can affect the charge, acidity, alkalinity, solubility, viscosity and other properties of HG, and also affect its pharmaceutical properties such as absorption and distribution in the body.
  • the present invention also provides another preparation method of oligogalacturonic acid polysaccharide, comprising the following steps: the first step, pretreatment of orange peel to obtain a stable water-soluble pectin gel; and the second step, alkali hydrolysis- Microwave treatment, under the conditions of controlling the pH at 12.0-13.0 and heating with microwaves to 80-100°0, adding sodium hydroxide to the stable water-soluble pectin gel to form a bond-breaking water-soluble pectin gel ; the third step, demethoxyl treatment, demethoxylation treatment is carried out to the water-soluble pectin gel with broken bonds, to obtain the crude product demethoxyl water-soluble pectin gel; the fourth step, super Membrane purification, using ultrafiltration membrane for fine extraction, the ultrafiltration membrane has a pore size of 1-10nm, keeps low pressure difference of 0.05-0.5MPa for continuous high-flow extraction, and has a molecular weight cut-off of 10 3 -10 4 .
  • the demethoxy treatment specifically includes: freeze-drying and concentrating, adjusting the concentration of crude pectin to 10-20 g/L, adding NaOH, maintaining the pH at 9-10, React at 4°C for 8-48 hours for demethylation, and finally use 10% glacial acetic acid to adjust the acidity and terminate the reaction; after the third step, rough extraction of the crude demethoxylated water-soluble pectin gel , after crude extraction treatment, if the content of galacturonic acid polysaccharide exceeds 70%, it will be degraded by enzymatic hydrolysis; if it does not exceed 70%, it will be treated by yeast fermentation; Low temperature drying treatment.
  • the enzymatic degradation treatment first use the isoelectric point method to deproteinize, adjust the pH value of acetic acid buffer to 4.5, and adjust the final concentration of pectin to 2-5wt%; add solidification Pectinase: lyase (PL, enzyme activity 32U/g), specific endo-polygalacturonases (endo-PG, E.C.3.2.1.15, 4212U/g), pectin esterase ( PE, E.C.3.1.1.11, 66.7U/g) and protopectinase, the pH is controlled at 3.0-6.0, and 45°5 (up to 60°0) is maintained for 60-90 minutes; the yeast fermentation process: Saccharomyces cerevisiae active dry yeast is added with 2wt% sucrose solution, stirred evenly, placed at 25-30°5 for 2-4 hours to activate it; in 2-5wt% pectin aqueous solution, add 1-5wt% activated
  • the content of galacturonic acid in the above-mentioned oligogalacturonic acid polysaccharide of the present invention is 93-98%, and the degree of esterification is 12-14%.
  • the present invention combines traditional Chinese medicine medical theory and adds several herbs for treating spleen deficiency and yingwei qi. Adding and subtracting, modifying and perfecting, the above-mentioned prescription with comprehensive effects such as promoting digestion, anti-inflammation, and enhancing immunity can be obtained.
  • Galacturonic acid polysaccharides can regulate the function of MDSC cells, T cells and neutrophils by antagonizing the galectin (Galectin) family ligands on the surface of immune cells, and realize the MDSC cells as the core.
  • the compound not only has the function of immune regulation, but also has the function of increasing white blood cells, can reduce the hematological toxicity of chemotherapy, and has no obvious toxic and side effects on the body when used alone.
  • oligogalacturonic acid polysaccharide complex used in the present invention follows the principles of traditional Chinese medicine to carry out the compatibility of monarchs and ministers. It is different from conventional Chinese medicines that exert antibacterial and anti-inflammatory effects. "Zuo Shi” assists the core component HG to nourish the spleen and stomach, support its anti-chronic inflammation function, enhance the overall function of the body, and enhance the anti-inflammatory and anti-oxidative stress effects of HG.
  • MCP/LCP is mainly aimed at removing heavy metals in the body, controlling tumor metastasis and other functions, and does not target oxidative stress and chronic inflammatory responses of inflammatory cytokines Galectin such as MDSC, Treg, etc.
  • Galectin such as MDSC, Treg, etc.
  • HG is added with traditional Chinese medicines astragalus, hawthorn, red dates, and tangerine peel in order to enhance its anti-chronic inflammation effect, enhance its function from the perspective of nourishing qi, invigorating the spleen, and promoting dampness, and achieve the effect of 1+1>2.
  • the dosage of Astragalus membranaceus is not large. It is used unilaterally. The dosage is 30-60g/day. It can be ground into powder and taken directly, or it can be decocted and extracted. It has obvious effects of raising blood pressure, producing white blood cells, and anti-inflammation. It has the effects of replenishing qi and solidifying the surface, promoting diuresis and reducing swelling. As the minister and assistant of HG, it can increase its oral availability, but the purpose is not to enhance the effect of HG on antagonizing inflammatory cells, but to supplement the deficiency of HG.
  • Astragalus is the main compound of traditional Chinese medicine, and other auxiliary medicines, red dates are for invigorating the spleen, neutralizing, invigorating qi and nourishing blood, coordinating the functions of other herbs, and balancing the regulation of qi and blood.
  • Hawthorn is for promoting blood circulation, digestion and accumulation, promoting qi and dispelling blood stasis, mainly to promote appetite and help promote qi and blood circulation.
  • Raw hawthorn also contains a large amount of vitamin C and flavonoids, which explain its mechanism of promoting blood circulation and dilating blood vessels from the theory of Western medicine, which can enhance the main functions of astragalus, resist inflammation, and increase white blood cells. Tangerine peel promotes qi, increases qi movement, strengthens the operation mechanism of other herbs, and solves the problem of spleen and stomach stagnation and loss of appetite.
  • tangerine peel promotes qi
  • hawthorn promotes blood
  • red dates nourishes blood
  • astragalus nourishes qi.
  • the amount of galacturonic acid polysaccharides in parts by weight, can be 610 parts, 620 parts, 630 parts, 640 parts, 650 parts, 660 parts , 670 parts, 680 parts, 690 parts, 700 parts, 710 parts and any value between 610-710 parts;
  • the amount of Radix Astragali can be any value between 25 parts, 30 parts, 35 parts and 25-35 parts;
  • the amount of fried hawthorn can be 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts, 11 parts, 12 parts, 13 parts, 14 parts, 15 parts, 16 parts, 17 parts, 18 parts, 19 parts , 20 parts, 21 parts, 22 parts, 23 parts, 24 parts, 25 parts and any value between 5-25 parts;
  • the amount of red dates can be 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts parts, 11 parts, 12 parts, 13 parts, 14 parts, 15 parts, 16 parts, 17 parts, 18 parts, 19 parts, 20 parts,
  • the red dates are sliced red dates obtained by removing pits and slicing.
  • the present invention also provides a preparation method of galacturonic acid polysaccharide complex, comprising:
  • the extract and galacturonic acid polysaccharide are mixed to obtain a galacturonic acid polysaccharide complex.
  • the pretreatment includes washing, ultrasonic pulverization and sieving performed in sequence.
  • the solid-to-liquid volume ratio of the soaking is 1:5-15, and the soaking time is 20-60 minutes.
  • the solid-liquid volume ratio of the soaking can be any value between 1:5, 1:10, 1:15 and 1:5-15, and the time can be 20min, 30min, 40min, 50min, 60min and Any value between 20-60min.
  • the decocting time is 30-90min.
  • the decocting time can be any value between 30 min, 40 min, 50 min, 60 min, 70 min, 80 min, 90 min and 30-90 min.
  • the present invention also provides an application of the galacturonic acid polysaccharide complex in the preparation of medicines, food or health care products for treating diseases related to chronic inflammation.
  • the chronic inflammation-related diseases include MDSC-related chronic inflammation, oxidative stress, free radical damage, leukopenia and imbalance of T cell subsets.
  • the oligogalacturonic acid polysaccharide complex is non-toxic to mammals (the U.S. FDA does not limit the upper limit of the administration of modified pectin), and can be directly used to prevent or treat chronic Inflammation-related diseases, or mixed with a pharmaceutically acceptable carrier, etc., to form a pharmaceutical form.
  • Examples of pharmaceutically acceptable carriers include: various organic or inorganic carrier substances commonly used as carriers, for solid preparations, excipients, lubricants, binders or disintegrating agents can be added; for liquid preparations, solvents, Solubilizer, buffer. Additives such as preservatives, sweeteners, coloring agents, antioxidants can be added if necessary.
  • Excipients can be selected from lactose, sucrose, mannitol, sorbitol, starch, dextrin, crystalline cellulose, hydroxypropyl cellulose, sodium carboxymethyl cellulose and the like.
  • the lubricant can be selected from magnesium stearate, calcium stearate and the like.
  • the binder may be selected from sucrose, gelatin, gum arabic, methylcellulose, carboxymethylcellulose and the like.
  • the solvent can be selected from sterile water, distilled water, ethanol, propylene glycol, corn oil, olive oil and the like.
  • the solubilizing agent can be selected from polyethylene glycol, propylene glycol, mannitol, trehalose, cholesterol, sodium citrate, sodium salicylate, sodium acetate and the like.
  • the buffering agent may be selected from buffers such as acetate, carbonate, citrate and the like.
  • the preservative may be selected from chlorobutanol, benzyl alcohol, sorbic acid, phenylethyl alcohol and the like.
  • the sweetener can be selected from sodium saccharin, aspartame, acesulfame potassium and the like.
  • Antioxidants may be selected from sulfites, ascorbates, and the like.
  • the oligogalacturonic acid polysaccharide complex of the present invention can be in the following forms: tablets, pills, powders, granules, capsules, syrups, lozenges, emulsions, suspensions, aerosols, and injections.
  • the galacturonic acid polysaccharide complex preparation accounts for 5-95% of the mass %.
  • the dosage of the oligogalacturonic acid polysaccharide complex is 100-500 mg/kg body weight ⁇ day, preferably 150-300 mg/kg body weight ⁇ day.
  • the frequency of taking the galacturonic acid polysaccharide complex is once a day, twice a day or three times a day.
  • the galacturonic acid polysaccharide complex can be taken continuously for more than 3 days, preferably, it can be taken continuously for 3 days to 100 days.
  • the dosage of the galacturonic acid polysaccharide complex is 200-400 mg/kg body weight ⁇ day.
  • the galacturonic acid polysaccharide complex is taken once a day, twice a day, three times a day or four times a day for 5-80 consecutive days.
  • the beneficial effects of the present invention include:
  • the galacturonic acid polysaccharide provided by the present invention is a composition that has clear immune cell targets, anti-inflammatory factors, anti-chronic inflammation, anti-oxidative free radicals, and can also increase the level of white blood cells.
  • the oligogalacturonic acid polysaccharide of the present invention can antagonize chronic inflammation related to MDSC cells. Synergistic effect with astragalus, fried hawthorn, red dates and tangerine peel has a more superior anti-chronic inflammation effect.
  • peripheral blood and tumor infiltrating lymphocytes When used in healthy people, it can reduce oxidative stress, chronic inflammation, free radical damage and premature aging diseases, and eliminate sub-health status; when used in cancer patients, it can relieve the immunosuppressive effect in the tumor microenvironment and increase CD8 effector T cells
  • the proportion in peripheral blood and tumor infiltrating lymphocytes can enhance the body's anti-tumor immunity, and at the same time, it can increase white blood cells and reduce the hematological toxicity of chemotherapy.
  • the preparation method of the oligogalacturonic acid polysaccharide complex provided by the invention has simple process, high yield and low cost.
  • the oligogalacturonic acid polysaccharide complex provided by the invention can be widely used in medicine, food or health products.
  • the present invention provides the following technical solutions:
  • a method for preparing galacturonic acid polysaccharides comprising the following steps:
  • Step 1 providing pectin-containing peel and/or pomace
  • Step 2 contact the raw material obtained in step 1 with an alkaline aqueous solution for alkali treatment, and keep the pH of the mixture not lower than 11 to obtain a bond-breaking water-soluble pectin gel; preferably, the pH of the alkali treatment is 12-13 , preferably for at least 30 minutes, such as 30, 40, 50, 60, 70, 80, 90, 100, 110 or 120 minutes;
  • Step 3 optionally concentrate the bond-breaking water-soluble pectin gel obtained in step 2, keep at pH 9-11 and temperature 0-8°C for at least 2 hours, then adjust the pH to near neutrality such as 6-8, Demethoxylating the bond-breaking water-soluble pectin gel to obtain crude demethoxyl water-soluble pectin gel; preferably using freeze-drying to concentrate; preferably concentrating to crude pectin Concentration of at least 5g/L, such as 10, 15, 20, 25, 30 or 40g/L, specifically such as 10-20g/L; preferably a pH of 9-10, preferably for 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 18, 20, 24, 30, 36, 40, 48, 60, 72 hours or more;
  • Step 4 optionally using a cation exchange resin to crudely extract the water-soluble pectin gel, such as a sulfonic acid-based or DEAE-based cation-exchange resin; and
  • Step 5 Remove high-molecular-weight impurities, preferably using an ultrafiltration membrane with a molecular weight cut-off of at least 10 3 -10 4 Da to remove high-molecular-weight impurities, for example, the ultrafiltration membrane has a pore size of 1-10 nm and keeps a low pressure difference of 0.05 -0.5MPa continuous high-flow extraction, molecular weight cut-off 10 3 -10 4 Da.
  • the acid treatment is carried out at a pH of 5-6, preferably for 10-60 minutes, eg 10, 15, 20, 30, 40, 45, 50, 60, 75, 90 or 120 minutes.
  • cellulase enzymolysis treatment is also carried out before or after the alkali treatment in step 2; preferably 1-10mg/g cellulase is added, and the enzymolysis temperature is ambient temperature to 40°C, such as 38°C, for at least 30 minutes, such as for 30, 40, 45, 50, 60, 70, 75, 80, 90, 100, 120 or 150 minutes.
  • pericarp and/or pomace are from citrus, pome fruit, grape, Cucurbitaceae, Musaceae fruit or sunflower plate, for example orange, tangerine, orange , kumquat, lemon, pomelo, kumquat, apple, pear, loquat, hawthorn, apricot, plum, plum, peach, kiwi, banana, grape, watermelon, sunflower.
  • step 6 The method according to any one of technical schemes 1 to 5, wherein the crude extraction product of step 4 is subjected to enzymolysis or fermentation treatment, if the content of galacturonic acid in the crude extraction product is at least 70%, then the crude extraction product Carry out enzymatic degradation treatment; if the content of oligogalacturonic acid in the crude extraction product is less than 70%, the crude extraction product is subjected to yeast fermentation treatment; wherein
  • the enzymatic degradation treatment includes: adjusting the final concentration of pectin to 2-5wt%, carrying out isoelectric point deproteinization at pH 4.5, and then adding solidified pectinase to the deproteinized product: lyase (PL, enzyme activity 32U /g), specific endopolygalacturonases (Endo-polygalacturonases, endo-PG, E.C.3.2.1.15, 4212U/g), pectin esterase (PE, E.C.3.1.1.11, 66.7U/g) and protopectinase, pH controlled at 3.0-6.0, for at least 30 minutes, such as 30, 40, 45, 50, 60, 70, 75, 80, 90, 100, 110, 120 minutes or longer, preferably a temperature of at least 37°C or more, such as 40, 42, 45, 50, 55 or 60°C; and
  • the yeast fermentation treatment adjust the final concentration of pectin to 2-5wt%, add 1-5wt% activated Saccharomyces cerevisiae; preferably the fermentation temperature is from ambient temperature to 35, preferably 30°C, preferably fermentation For at least 12 hours, such as 12, 18, 24, 36, 48 hours or more.
  • alkaline pH is independently achieved using a strong base, such as being selected from NaOH, KOH or CaOH or a mixture thereof, and/or the acidic pH is independently Preferably, it is achieved using a dilute acid, for example selected from hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, sulfurous acid, acetic acid or mixtures thereof.
  • the extract and galacturonic acid polysaccharide are mixed to obtain the edible composition.
  • the galacturonic acid polysaccharide prepared by any one of the methods of technical schemes 1 to 8, and the edible composition described in technical scheme 9, are used to treat diseases related to chronic inflammation, preferably in the form of medicines, food or health products form.
  • the present invention also provides the following technical solutions:
  • a preparation method of galacturonic acid polysaccharide is characterized in that, comprises the following steps:
  • the orange peel is pretreated to obtain a stable water-soluble pectin gel
  • the second step is alkali hydrolysis-microwave treatment. Under the conditions of controlling the pH at 12.0-13.0 and heating to 80-1003 by microwave, sodium hydroxide is added to the stable water-soluble pectin gel to form a bond-breaking water-soluble gel. pectin gel;
  • demethoxylization treatment is performed on the bond-breaking water-soluble pectin gel to obtain a crude demethoxylization water-soluble pectin gel
  • the fourth step is ultrafiltration membrane refining, using ultrafiltration membrane for fine extraction, the ultrafiltration membrane has a pore size of 1-10nm, keeps a low pressure difference of 0.05-0.5MPa for continuous high-flow extraction, and has a molecular weight cut-off of 10 3 -10 4 .
  • the demethoxy treatment specifically includes: freeze-drying and concentrating, adjusting the concentration of crude pectin to 10-20g/L, adding NaOH, maintaining the pH at 9-10, and reacting at 4°C for 8-48h Demethylation, and finally use 10% glacial acetic acid to adjust the acidity and terminate the reaction;
  • the crude demethoxylated water-soluble pectin gel is subjected to a rough extraction treatment, and after the rough extraction treatment, if the galacturonic acid polysaccharide content exceeds 70%, it is subjected to an enzymatic degradation treatment; More than 70% are processed by yeast fermentation;
  • concentration by rotary evaporation under reduced pressure and drying at low temperature are also included.
  • the enzymatic degradation treatment first use the isoelectric point method to deproteinize, adjust the pH value of acetic acid buffer to 4.5, and adjust the final concentration of pectin to 2-5wt%; add solidified pectinase: lyase (PL, enzyme activity 32U/g), specific endopolygalacturonases (Endo-polygalacturonases, endo-PG, E.C.3.2.1.15, 4212U/g), pectin esterase (PE, E.C.3.1.1.11, 66.7U/g ) and protopectinase, the pH is controlled at 3.0-6.0, and maintained at 45°C (up to 60°C) for 60-90 minutes;
  • the yeast fermentation treatment adding 2wt% sucrose solution to saccharomyces cerevisiae active dry yeast, stirring evenly, placing it at 25-30°C for 2-4 hours to activate it; adding 1- 5wt% of the activated yeast is fermented at 30°C for 24-48 hours.
  • the galacturonic acid content in the described galacturonic acid polysaccharide is 93-98%, The degree of esterification is 12-14%.
  • the galacturonic acid polysaccharide complex characterized in that, in parts by weight, comprising:
  • the molecular weight of the oligogalacturonic acid polysaccharide is 3kDa to 8kDa.
  • the preparation method of the oligogalacturonic acid polysaccharide compound described in technical scheme 5, is characterized in that, comprises the following steps:
  • the extract and galacturonic acid polysaccharide are mixed to obtain a galacturonic acid polysaccharide complex.
  • the galacturonic acid polysaccharide complex described in technical scheme 5 and the galacturonic acid polysaccharide complex prepared by the method described in any one of technical schemes 6-9 are used in the preparation and treatment of diseases related to chronic inflammation Applications in medicine, food or health products.
  • Fig. 1 shows that in vitro experiments, oligogalacturonic acid polysaccharide complexes have no toxic effect on the growth of mouse fibroblasts;
  • Figure 2 is a comparison photo showing the qualitative analysis of 4T1 cells formed by trypan blue staining
  • Figure 3 is a graph showing the comparison of MDSC cell ratios in the mouse breast cancer 4T1 xenograft tumor chemotherapy treatment model experiment
  • Figure 4 is a graph showing the comparison of the levels of immunosuppressive cells MDSC and Treg cells in the mouse breast cancer 4T1 xenograft tumor chemotherapy treatment model experiment;
  • Figure 5 is a graph showing the comparison of the levels of immune-enhancing cells Th1, Th17 and CD8 + killer T cells in the mouse breast cancer 4T1 xenograft tumor chemotherapy treatment model experiment;
  • Fig. 6 is a graph showing the comparison of the proportion of neutrophils in the mouse breast cancer 4T1 xenograft tumor chemotherapy treatment model experiment
  • Figure 7 is a graph showing the comparison of mouse body weight curves in the mouse LPS-induced chronic inflammation experiment.
  • Figure 8 is a graph showing the comparison of the levels of immunosuppressive cells MDSC and Treg cells in the chronic inflammation experiment induced by mouse LPS;
  • Figure 9 is a graph showing the comparison of the levels of immune-enhancing cells Th1, Th17 and CD8 + killer T cells in the LPS-induced chronic inflammation experiment in mice.
  • Acidification pretreatment dissolve the broken pericarp with dilute hydrochloric acid or sulfurous acid, control the pH value at 5.0-6.0, 30min, form a stable water-soluble pectin gel, filter to remove slag;
  • Enzymolysis add 6mg/g cellulase, maintain the temperature at 38°C, and enzymolysis time 70min;
  • Alkaline hydrolysis-microwave method In a closed culture tank, add an equivalent amount of 4mol/L NaOH to the crude pectin gel aqueous solution, control the pH at 12.0-13.0, and heat it to 80-100°0 with microwaves. Microwave energy can cause Water molecular resonance, breaking the covalent bond of long-chain polysaccharides in advance, shortening the subsequent enzymatic hydrolysis or microbial fermentation process time and raw material consumption, stirring for 40-120min, and rapidly cooling to room temperature;
  • Demethoxylation lyophilize and concentrate, adjust the concentration of crude pectin to 10-20g/L, add NaOH, maintain the pH at 9-10, react at 4°C for 8-48h for demethylation, and finally use 10 % glacial acetic acid, adjust the acidity, terminate the reaction;
  • the crude pectin product has uniform molecular weight, stable chemical properties, and the crude HG content has reached more than 70%, it can be degraded by enzymatic hydrolysis; if the crude HG content does not reach 70%, enter the yeast fermentation method;
  • Enzymatic degradation first use the isoelectric point method to deproteinize, adjust the pH value of the acetate buffer to 4.5, and adjust the final concentration of pectin to 2-5%.
  • Ultrafiltration membrane refining use ultrafiltration membrane for fine extraction, the pore size of the ultrafiltration membrane is 1-10nm, keep a low pressure difference of 0.05-0.5MPa for continuous high-flow extraction, and the molecular weight cut-off is 10 3 -10 4 ;
  • the content of galacturonic acid was determined by m-hydroxybiphenyl colorimetry, and the degree of esterification was determined by volumetric analysis.
  • the measured content of galacturonic acid is 95%, and the degree of esterification is 12%.
  • Enzymolysis add 5mg/g cellulase, maintain the temperature at 38°C, and enzymolysis time 90min;
  • HG does not reach 70%, no pre-deproteinization step is required, use Saccharomyces cerevisiae fermentation method to prolong the fermentation degradation time: add active dry yeast of Saccharomyces cerevisiae to 2% sucrose solution, stir well, 25-30 ° 5 Place it for 2-4 hours to activate it; add 1-5% activated yeast to 2-5% aqueous pectin solution, ferment for 24-48 hours at 30°C;
  • the pore size of the ultrafiltration membrane is 1-10nm, maintain a low pressure difference of 0.05-0.5MPa for continuous high-flow extraction, and the molecular weight cut-off is 10 3 -10 4 ;
  • the content of galacturonic acid was determined by m-hydroxybiphenyl colorimetry, and the degree of esterification was determined by volumetric analysis.
  • the measured galacturonic acid content is 93%, and the degree of esterification is 14%.
  • the galacturonic acid polysaccharide prepared in Example 1 was used.
  • the galacturonic acid polysaccharide prepared in Example 1 was used.
  • the oligogalacturonic acid polysaccharide complex was prepared according to the method in Example 3, without adding fried hawthorn, red dates and tangerine peel.
  • the galacturonic acid polysaccharide prepared in Example 1 was used. Prepare 600 parts by weight of galacturonic acid polysaccharide, 35 parts by weight of astragalus, 10 parts by weight of fried hawthorn, 20 parts by weight of red dates and 6 parts by weight of tangerine peel.
  • the galacturonic acid polysaccharide prepared in Example 1 was used.
  • Embodiment 6 has no toxic effect
  • the galacturonic acid polysaccharide compound (hereinafter referred to as HG+Chinese medicine compound for short) of embodiment 3 is configured according to the optimal ratio, containing 625 parts by weight of galacturonic acid polysaccharide, 25 parts by weight of Radix Astragali, and 10 parts by weight of fried hawthorn part, 10 parts by weight of red dates and 8 parts by weight of tangerine peel.
  • the polygalacturonic acid polysaccharide complex of the present application has no obvious toxic effect on the growth of mouse fibroblasts.
  • Rat macrophages RAW264.7 in the logarithmic growth phase were inoculated in a 96-well culture plate at a density of 5 to 3 W2/8026 complete DMEM medium, and a blank group, a control group, and sample groups with different concentrations were set up.
  • Six parallel wells were cultured in a 37°7, 5% (v/v) CO 2 incubator. Cultivate overnight, until the next day the cell density reaches 50-60%, add medium and different concentrations of galacturonic acid polysaccharide complex pretreatment for 8 hours (the galacturonic acid polysaccharide complex of embodiment 3 ).
  • Blank control group only add 100 complete DMEM culture medium according to group;
  • Positive control group Add 100 g of complete medium containing LPS to each well for culture, so that the final concentration of LPS is 500 ng/ml;
  • Treatment group 1 add the complete DEME culture medium that contains oligogalacturonic acid polysaccharide complex in 100 bases in culture medium, make the final concentration of galacturonic acid polysaccharide complex be 2 acid polysaccharide complexes
  • Treatment group 2 add 100 bases in the culture medium and contain the complete DEME medium of oligogalacturonic acid polysaccharide complex, make the final concentration of galacturonic acid polysaccharide complex be 4 acid polysaccharide complex
  • Treatment group 3 add the complete DEME culture medium that contains oligogalacturonic acid polysaccharide complex in 100 bases in culture medium, make the final concentration of galacturonic acid polysaccharide complex be 8 acid polysaccharide complex
  • Treatment group 4 Add 100 bases of complete DEME medium containing galacturonic acid polysaccharide complexes in the culture medium, so that the final concentration of galacturonic acid polysaccharide complexes is 16 polysaccharide complexes.
  • the oligogalacturonic acid polysaccharide complex of the present application has the effect of antagonizing the proliferation and differentiation of immunosuppressive cells related to chronic inflammation: MDSC and Treg cells in vitro.
  • oligogalacturonic acid polysaccharide complex can significantly reduce the proportion of MDSC cells in the spleen of tumor-bearing mice.
  • oligogalacturonic acid polysaccharide complex reduces the differentiation ratio of immunosuppressive cells MDSC and Treg cells.
  • the spleen cells of tumor-bearing mice were cultivated for 1 cell culture 6.
  • the control group was added with 20 normal saline per well.
  • the final volume was 1ml, and the cell culture was terminated after 48 hours, and the proportion of IFN + Th1 cells, IL-17a + Th17 cells and CD8 + killer T cells, the proportion of CD4 + CD25 hi suppressive Treg cells, and CD11b + Gr-1 + suppressive MDSC cell ratio.
  • the results are shown in Figure 4 and Figure 5.
  • Example 9 The oligogalacturonic acid polysaccharide complex has the effect of increasing white blood cells and reducing the hematological toxicity of chemotherapy
  • mice 8-10 weeks old Balb/c female mice were randomly divided into 5 groups, 8 mice in each group:
  • Blank group intraperitoneal injection of 100: abdominal saline;
  • Positive control group and treatment group intraperitoneal injection of low-dose LPS (0.5 mg/kg body weight, 50, m, once every 3 days) 8 times, from day 0 to day 21;
  • the galacturonic acid polysaccharide treatment group use low-dose LPS intraperitoneal injection (0.5mg/kg body weight, 50, m, once in 3 days), the 0th day begins, daily oral galacturonic acid polysaccharide (embodiment 1), the oral dose is 2g/kg body weight per day;
  • the treatment group of galacturonic acid polysaccharide + astragalus intraperitoneal injection of low-dose LPS (0.5mg/kg body weight, 50, m, once every 3 days), starting from day 0, daily oral administration of galacturonic acid polysaccharide + Radix Astragali (comparative example 1), oral dosage is 2.03g/kg body weight day;
  • the treatment group of galacturonic acid polysaccharide compound intraperitoneal injection of low-dose LPS (0.5mg/kg body weight, 50, m, once every 3 days), starting from day 0, daily oral administration of galacturonic acid polysaccharide compound thing (embodiment 3), oral dose is 2.17g/kg body weight ⁇ day.
  • mice were in a normal state of mind, eating and drinking normally, and no obvious abnormal feeding, exercise, and excretion behaviors were found;
  • mice were in low spirits, malaise, reduced food and water intake, slow response to stimuli, lassitude or irritability, significant weight loss, hair loss, no obvious abnormality in urination, loose and soft stool , Occasionally have mucus, mucus, pus and blood in the stool.
  • HG + astragalus treatment group Polygalacturonic acid polysaccharide + astragalus treatment group: the spirit of the mice improved, the amount of food and water consumed returned to basically normal, the body weight increased slowly from normal, sparse hair was not common, and no obvious abnormalities were seen in urine , Stool forming, occasional mucus stool.
  • oligogalacturonic acid polysaccharide compound (HG+Chinese medicine compound treatment group): good mental state, normal eating and drinking, sensitive and active movements, normal weight gain, bright coat color, formed stool, oval shape Granular, yellowish brown, hard texture, no mucus, no pus and blood.
  • mice spleen cells were extracted and analyzed by flow cytometry.
  • the results showed that long-term treatment of low-concentration LPS in the peritoneal cavity caused a significant increase in spleen immunosuppressive cells in the positive control group: MDSC and Treg cells; oligomerization Both galacturonic acid polysaccharide and oligogalacturonic acid polysaccharide + Astragalus treatment group can reduce the increase in the proportion of MDSC cells and Treg cells caused by chronic inflammation caused by LPS treatment; oligogalacturonic acid polysaccharide complex Compared with the galacturonic acid polysaccharide group and the galacturonic acid polysaccharide + astragalus treatment group, the treatment group can significantly reduce the increase of immunosuppressive cells MDSC and Treg cells caused by chronic inflammation of LPS.
  • Figure 8 The result is shown in Figure 8.
  • Table 2 The proportion of MDSC and Treg cells in different treatment groups in the anti-inflammatory experiment of LPS mice.
  • mouse spleen cells were extracted and analyzed by flow cytometry, and the proportions of IFN + Th1 cells, IL-17a + Th17 cells and CD8 + killer T cells were detected by flow cytometry. The result is shown in Figure 9.
  • FIG. 9 shows that the galacturonic acid polysaccharide complex increases the differentiation ratio of immune positive effector cells Th1, Th17 and CD8 + killer T cells.
  • oligogalacturonic acid polysaccharide complex provided by the present application has no obvious killing effect on mouse fibroblasts in vitro experiments, and can also regulate immune cell differentiation, and has the ability to reduce the proportion of CD4 regulatory T cells, The effect of reducing the proportion of MDSC cells.
  • galacturonic acid polysaccharides After oral administration of galacturonic acid polysaccharides to mice, it can antagonize chronic inflammation associated with MDSC cells in vivo, reduce the proportion of CD4Treg cells in peripheral blood, and increase the proportion of CD8T cells.
  • the galacturonic acid polysaccharide complex of the present application has a good antagonism of chronic inflammation associated with MDSC cells, can reduce the proportion of peripheral blood CD4Treg cells, and increase the proportion of CD8T cells. Effect.
  • the oligogalacturonic acid polysaccharide complex provided by this application has the new functions of enhancing immunity, protecting the liver, anti-chronic inflammation, anti-oxidative stress, and anti-aging, and it can be used for the preparation of medicines, food or health care
  • the drug, food or health product can be used for the treatment of MDSC-related chronic inflammation, and has the treatment value of increasing white blood cells and reducing the hematological toxicity of chemotherapy.
  • first and second are used for descriptive purposes only, and cannot be interpreted as indicating or implying relative importance or implicitly specifying the quantity of indicated technical features.
  • the features defined as “first” and “second” may explicitly or implicitly include at least one of these features.
  • “plurality” means at least two, such as two, three, etc., unless otherwise specifically defined.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • General Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Polymers & Plastics (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Materials Engineering (AREA)
  • Sustainable Development (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

本发明提供了低聚半乳糖醛酸多糖、复合物及其制备方法和应用。本发明提供了一种低聚半乳糖醛酸多糖的制备方法，包括以下步骤：第一步，预处理，得到稳定水溶性果胶凝胶体；以及第二步，碱水解-微波法处理；第三步，脱甲氧基处理；第四步，超滤膜精制。本发明还提供了利用该多糖的复合物及其制备方法和应用。本发明的所述复合物具有良好的医用效果，且制备方法工艺简单，得率高，成本低。

Description

低聚半乳糖醛酸多糖、复合物及其制备方法和应用
本申请要求于2021年9月8日提交中国专利局、申请号为202111050134.0、发明名称为“低聚半乳糖醛酸多糖、复合物及其制备方法和应用”的中国专利申请的优先权，其全部内容通过引用结合在本申请中。
技术领域
本发明涉及多糖领域，尤其涉及低聚半乳糖醛酸多糖、复合物及其制备方法和应用。
背景技术
低聚半乳糖醛酸多糖(Homogalacturonan，HG)是从以苹果果渣、葵花盘、柑橘皮、柠檬皮等为原料生产的“改性果胶”(Modified citrus pectin，MCP)中提取的，果胶多糖经水解降酯后，分子量更小、无支链的纤维，其化学成分均一，易溶解，口服易吸收。
小分子柑橘果胶(LCP)是美国圣特莱公司继以橘皮为原料的“改性果胶”之后的第二代产品，是一种混合物，化学成分不稳定，其分子量跨度在10kDa-20kDa，酯化度在10％至25％不等。小分子柑橘果胶LCP是各种多糖的混合物，含有鼠李半乳糖醛酸聚糖I(Rhamngalacturonan I，RGI)、鼠李半乳糖醛酸聚糖II(Rhamngalacturonan II，RGII)、半乳糖醛酸聚糖(Homogalacturonan，HG)和木糖半乳糖醛酸聚糖(Xylogalacturonan，XG)，阿拉伯聚糖、阿拉伯半乳聚糖I和阿拉伯半乳聚糖II等其他糖链。
现有文献已经报道了，半乳凝素(Galectin-3)能直接介导血液中的肿瘤细胞间聚集，肿瘤细胞与基质间的识别和黏附。已经证实多种高转移性肿瘤细胞均能高水平表达Galectin-3，并在原发肿瘤和转移瘤病灶中均能检测到Galectin-3的高表达，其表达增加与肿瘤的生长、转移呈正相关，可以作为某些肿瘤恶性病变的鉴别诊断标志。因此，通常认为可以通过封闭或阻断Galectin-3介导的黏附聚集作用达到治疗和控制癌症转移的目的。
MCP是Galectin-3的一个高亲和力配体，对体内Galectin-3配体有竞争性抑制作用。Platt等(Platt D et al.,Modulation of the lung colonization of B16-F1 melanoma cells by citrus pectin[J].JNCI Cancer Spectrum,1992,84(6):438)通过体外细胞凝集实验和细胞黏附试验证实，MCP可通过封闭细胞表面的Galectin-3而抑制细胞间的相互识别和黏附功能。当MCP达到一定浓度时，肿瘤细胞表面Galectin-3几乎被MCP结合封闭，从而可阻断细胞间的相互识别和聚集。一些动物实验证实MCP能有效抑制肿瘤的生长转移。
在本发明被公布之前，尚未有任何专利公开或报道过本专利申请中提及的低聚半乳糖醛酸多糖，对介导氧化应激、慢性炎症的炎症因子Galectin-3和免疫细胞MDSC，具有体外拮抗MDSC增殖的功能，体内抑制MDSC在脾脏聚集，减轻全身性慢性炎症的作用。
本发明的目的是提供低聚半乳糖醛酸多糖作为药品、食品或保健品的用途：消除Galectin-3相关的MDSC细胞分化、聚集，和MDSC调控的下游T细胞、中性粒细胞比例改变和功能改变，以及由此引发的全身性氧化应激、慢性炎症、自由基损伤和早老性疾病。其化学结构式如下：
Figure PCTCN2022117713-appb-000001
本发明发明人发现，化合物HG能通过拮抗MDSC细胞表面的配体Galectin-3而发挥对MDSC细胞的体外增殖拮抗、抑制体内MDSC聚集脾脏的作用，实现对MDSC引起的氧化应激、慢性炎症、自由基损伤和早老性疾病的控制。这种化合物本身，其单独使用对机体无明显毒副作用。低聚半乳糖醛酸多糖作为益生元，具有滋养肠道益生菌，辅助调节糖、脂代谢调节作用。现有文献检索中未见低聚半乳糖醛酸多糖及其衍生物的报道。
发明内容
本发明的目的在于提供一种具有抗炎作用的低聚半乳糖醛酸多糖及其制备方法和应用，以解决上述问题。
为实现以上目的，本发明提供了一种低聚半乳糖醛酸多糖的制备方法，所述制备方法包括以下步骤：
(1)碱裂解-微波法前处理；
(2)酶法/酵母发酵法降解；
(3)使用超滤膜进行精细提取，所述超滤膜孔径为1-10nm，保持低压力差0.05-0.5MPa持续高流通萃取，截留分子量在10 3-10 4；
(4)低温干燥，得到纯化的低聚半乳糖醛酸多糖。
本发明提供了一种低聚半乳糖醛酸多糖复合物，以重量份数计，包含：
低聚半乳糖醛酸多糖610-710重量份、黄芪25-35重量份、炒山楂5-25重量份、红枣5-25重量份和陈皮6-20重量份；
所述低聚半乳糖醛酸多糖的分子量为3kDa至7kDa，酯化度为5％-15％。
在一个优选的实施方案中，所述低聚半乳糖醛酸多糖复合物，以重量份数计，包含：
低聚半乳糖醛酸多糖620-640重量份、黄芪20-30重量份、炒山楂5-15重量份、红枣5-15重量份和陈皮6-15重量份；
所述低聚半乳糖醛酸多糖的分子量为3kDa至7kDa，酯化度为5％-15％。
在一个优选的实施方案中，本发明提供了一种低聚半乳糖醛酸多糖复合物，以重量份数计，包括：
低聚半乳糖醛酸多糖625重量份、黄芪25重量份、炒山楂10重量份、红枣10重量份和陈皮8重量份。
所述低聚半乳糖醛酸多糖中的半乳糖醛酸能够影响HG的电荷、酸碱性、溶解度、黏度等性质，而且会影响其在体内吸收和分布等药学性质。酯化度越高，溶解度越低，当酯化度降低时，有利于提高低聚半乳糖醛酸多糖的生物利用度。
本发明还提供了另外的低聚半乳糖醛酸多糖的制备方法，包括以 下步骤：第一步，对橙子果皮预处理，得到稳定水溶性果胶凝胶体；以及第二步，碱水解-微波法处理，在控制pH在12.0-13.0，微波加热至80-100°0条件下，向所述稳定水溶性果胶凝胶体中加入氢氧化钠，形成断键水溶性果胶凝胶体；第三步，脱甲氧基处理，对所述断键水溶性果胶凝胶体进行去甲氧基化处理，得到粗品脱甲氧基水溶性果胶凝胶体；第四步，超滤膜精制，使用超滤膜进行精细提取，所述超滤膜孔径为1-10nm，保持低压力差0.05-0.5MPa持续高流通萃取，截留分子量在10 3-10 4。
在一个优选的实施方案中，在第三步中，所述脱甲氧基处理具体为：冷冻干燥浓缩，调整粗果胶浓度为10-20g/L，加入NaOH，维持pH在9-10，于4℃反应8-48h进行去甲酯化，最后用10％冰醋酸，调整酸度，终止反应；第三步之后，对所述粗品脱甲氧基水溶性果胶凝胶体进行粗提处理，经过粗提处理后，低聚半乳糖醛酸多糖含量超过70％则进行酶解法降解处理；不超过70％的则进行酵母发酵法处理；第四步之后，还包括减压旋转蒸发浓缩，低温干燥处理。
根据本发明的优选方式，可选择的，所述酶法降解处理：先使用等电点法脱蛋白，醋酸缓冲液调整pH值为4.5，调整果胶终浓度为2-5wt％；加入固态化果胶酶：裂解酶(PL，酶活度32U/g)，特异性内切聚半乳糖醛酸(Endo-polygalacturonases，endo-PG，E.C.3.2.1.15，4212U/g)，果胶酯酶(PE，E.C.3.1.1.11，66.7U/g)和原果胶酶，pH控制在3.0-6.0，45°5(最高不超过60°0)维持60-90分钟；所述酵母发酵法处理：将酿酒活性干酵母加入2wt％蔗糖溶液，搅拌均匀，25-30°5放置2-4小时，使其活化；在2-5wt％浓度的果胶水溶液中，加入1-5wt％的活化好的酵母，30°0，发酵24-48小时。
本发明上述所述低聚半乳糖醛酸多糖中半乳糖醛酸含量为93-98％，酯化度为12-14％。
本发明在发现低聚半乳糖醛酸多糖具有抗慢性炎症和升白细胞方面的作用的基础上，结合中医医理，加入治脾虚、营卫气的几味药，在辨证施治过程中，不断尝试加减，修改完善，得到上述具有促消化、抗炎、增强免疫力等综合作用的方剂。
低聚半乳糖醛酸多糖能通过拮抗免疫细胞表面的半乳糖凝集素 (Galectin)家族配体，而发挥对MDSC细胞、T细胞、中性粒细胞的功能调节，实现对MDSC细胞为核心的上下游免疫细胞综合作用所导致的慢性炎症、全身性炎症的拮抗作用。这种化合物具有免疫调节功能的同时，还具有升白细胞功能，能减低化疗的血液学毒性，且其单独使用对机体无明显毒副作用。
本发明使用的低聚半乳糖醛酸多糖复合物，遵循中医医理进行君臣佐使配伍，与常规的发挥抗菌消炎作用的中药不同，性味非寒凉，不取其“攻”的效果，而是作为“佐使”对核心组分HG辅佐之，进行补益脾胃，支持其抗慢性炎症功能，增强机体整体机能，提升HG的抗炎症、抗氧化应激的效果。
MCP/LCP主要针对驱除体内重金属，控制肿瘤转移等功能，并不针对炎症细胞因子Galectin的氧化应激和慢性炎症反应比如MDSC、Treg等，之前也没有人发现MCP/LCP有增加化疗小鼠白细胞的作用。HG加上中药黄芪、山楂、红枣、陈皮是为了增强其抗慢性炎症效果，从补气、健脾、利湿的角度增强其功能，实现1+1＞2的效果。而如果要单独使用中药，实现抗炎、抗氧化应激的目的，需要根据中医医理，使用性味寒凉，主“攻”和“杀”的药物，会带来很多副作用，例如伤脾胃、伤气血。而现在，我们应用中医医理，以HG为君，山楂、红枣、陈皮作为佐使，通过调动这三味药补脾胃、补气、健脾利湿的作用，来增强HG的抗炎效果。
在临床上黄芪用量不大，单方使用，用量为30-60g/天，可以研粉直接服用，也可用水煎剂浸膏，有明显升血压、生白血球、抗炎作用，但此时，舍弃其益气固表、利水消肿的功效。作为HG的臣使辅佐，可以增加其口服利用度，但目的不是增强HG的拮抗炎症细胞的作用，而是补充HG不足之处。
中药复合物中黄芪是主要的，其他辅药，红枣是为了健脾和中、补气养血，协调其他几味药的功能，均衡气血的调控。山楂为了活血行血，消食化积，行气散瘀，主要为了促进胃口，帮助行气活血。生山楂还含有大量维生素C、黄酮类物质，从西医科学理论上解释其活血、扩血管机制，能增益黄芪的主要功能，抵抗炎症，提高白细胞。陈皮行气，增 加气机疏导，加强其他几味药的运行机理，解决脾胃停滞，胃口不开的问题。
所以陈皮行气，山楂行血，红枣补血，黄芪补气，各司其职，促进人体更好地吸收HG，辅助提高HG在体内运行的效率。
可选地，该低聚半乳糖醛酸多糖复合物中，以重量份数计算，低聚半乳糖醛酸多糖的用量可以是610份、620份、630份、640份、650份、660份、670份、680份、690份、700份、710份以及610-710份之间的任意值；黄芪的用量可以是25份、30份、35份以及25-35份之间的任意值；炒山楂的用量可以是5份、6份、7份、8份、9份、10份、11份、12份、13份、14份、15份、16份、17份、18份、19份、20份、21份、22份、23份、24份、25份以及5-25份之间的任意值；红枣的用量可以是5份、6份、7份、8份、9份、10份、11份、12份、13份、14份、15份、16份、17份、18份、19份、20份、21份、22份、23份、24份、25份以及5-25份之间的任意值；陈皮的用量可以是6份、7份、8份、9份、10份、11份、12份、13份、14份、15份、16份、17份、18份、19份、20份以及6-20份之间的任意值。
优选地，所述红枣为去核切片得到的红枣片。
本发明还提供了一种低聚半乳糖醛酸多糖复合物的制备方法，包括：
将黄芪、炒山楂、红枣和陈皮经预处理后用水浸泡，然后煎煮30-60min、过滤制备得到浸膏；
将所述浸膏和低聚半乳糖醛酸多糖混合得到低聚半乳糖醛酸多糖复合物。
优选地，所述预处理包括依次进行的清洗、超声粉碎和过筛。
优选地，所述浸泡的固液体积比为1：5-15，浸泡时间为20-60min。
可选地，所述浸泡的固液体积比可以为1:5、1:10、1:15以及1：5-15之间的任意值，时间可以为20min、30min、40min、50min、60min以及20-60min之间的任意值。
优选地，所述煎煮的时间为30-90min。
可选地，所述煎煮的时间可以为30min、40min、50min、60min、70min、 80min、90min以及30-90min之间的任意值。
本发明还提供了一种低聚半乳糖醛酸多糖复合物在制备治疗慢性炎症相关疾病的药品、食品或保健品中的应用。所述慢性炎症相关疾病包括MDSC相关慢性炎症、氧化应激、自由基损伤、白细胞降低和T细胞亚群比例失衡。
在一个优选的实施方案中，所述低聚半乳糖醛酸多糖复合物对哺乳动物无毒(美国FDA未限制改性果胶的服用上限)，并且可以直接用作预防或治疗哺乳动物的慢性炎症相关疾病，或与可药用载体等混合，形成药物形式。
可药用载体的例子包括：通常用作载体的各种有机或无机载体物质，对于固体制剂，可加入赋形剂、润滑剂、粘合剂或崩解剂；对于液体制剂，可加入溶剂、增溶剂、缓冲剂。必要时可以加入添加剂，如防腐剂、甜味剂、着色剂、抗氧化剂。
赋形剂可选自乳糖、蔗糖、甘露糖醇、山梨糖醇、淀粉、糊精、结晶纤维素、羟丙基纤维素、羧甲基纤维素钠等。
润滑剂可选自硬脂酸镁、和硬脂酸钙等。
粘合剂可选自蔗糖、明胶、阿拉伯胶、甲基纤维素、羧甲基纤维素等。
溶剂可选自无菌水、蒸馏水、乙醇、丙二醇、玉米油、橄榄油等。
增溶剂可选自聚乙二醇、丙二醇、甘露糖醇、海藻糖、胆固醇、枸橼酸钠、水杨酸钠和乙酸钠等。
缓冲剂可选自缓冲液，如乙酸盐、碳酸盐、柠檬酸盐等。
防腐剂可选自氯丁醇、苯甲醇、山梨酸、苯乙醇等。
甜味剂可选自糖精钠、阿斯巴甜、安赛蜜等。
抗氧化剂可选自亚硫酸盐、抗坏血酸盐等。
本发明的低聚半乳糖醛酸多糖复合物可以为以下形式：片剂、丸剂、粉剂、颗粒剂、胶囊剂、糖浆剂、锭剂、乳剂、混悬剂、气雾剂、注射剂。
所述低聚半乳糖醛酸多糖复合物在制备治疗慢性炎症相关疾病的药品中的应用中，相对于所述药品的总质量，所述低聚半乳糖醛酸多 糖复合制剂占5-95质量％。
所述低聚半乳糖醛酸多糖复合物的用量为100-500mg/kg体重·天，优选150-300mg/kg体重·天。所述低聚半乳糖醛酸多糖复合物的服用次数为每天一次、每天两次或每天三次。所述低聚半乳糖醛酸多糖复合物可以连续服用3天以上，优选地，可以连续服用3天-100天。
在一个优选的实施方案中，所述低聚半乳糖醛酸多糖复合物的用量为200-400mg/kg体重·天。
在一个优选的实施方案中，所述低聚半乳糖醛酸多糖复合物的服用次数为每天一次、每天两次、每天三次或每天四次，连续服用5-80天。
与现有技术相比，本发明的有益效果包括：
本发明提供的低聚半乳糖醛酸多糖，是一种有明确免疫细胞靶标的、抗炎症因子、抗慢性炎症、抗氧化自由基且兼具提升白细胞水平的组合物。本发明的低聚半乳糖醛酸多糖能拮抗MDSC细胞相关慢性炎症。与黄芪、炒山楂、红枣和陈皮协同作用具有更优越的抗慢性炎症的作用。在健康人中使用，能够减轻氧化应激、慢性炎症、自由基损伤和早老性疾病，消除亚健康状态；在肿瘤患者中使用，能解除肿瘤微环境中免疫抑制效应，增加CD8效应性T细胞在外周血和肿瘤浸润淋巴细胞里的比例，而提升机体抗肿瘤免疫力，同时具有升白细胞、减轻化疗血液学毒性的作用。
本发明提供的低聚半乳糖醛酸多糖复合物的制备方法，工艺简单，得率高，成本低。
本发明提供的低聚半乳糖醛酸多糖复合物可以广泛用于药品、食品或保健品。
作为说明，本发明提供了以下技术方案：
1.一种制备低聚半乳糖醛酸多糖的方法，包括以下步骤：
步骤1：提供含果胶的果皮和/或果渣；
步骤2：使步骤1获得的原料与碱性水溶液接触以进行碱处理，保持混合物pH值不低于11，以获得断键水溶性果胶凝胶体；优选地碱处理 pH值为12-13，优选地持续至少30分钟，例如30、40、50、60、70、80、90、100、110或120分钟；
步骤3：任选地将步骤2获得的断键水溶性果胶凝胶体浓缩，在pH9-11、温度0-8℃下持续至少2小时，然后调节pH至接近中性如6-8，对所述断键水溶性果胶凝胶体进行去甲氧基化处理，得到粗品脱甲氧基水溶性果胶凝胶体；；优选地使用冷冻干燥进行浓缩；优选地浓缩至粗果胶浓度至少5g/L，例如10、15、20、25、30或40g/L，具体地如10-20g/L；优选地pH值为9-10，优选地持续2、3、4、5、6、7、8、9、10、12、15、18、20、24、30、36、40、48、60、72小时或更长时间；
步骤4：任选地使用阳离子交换树脂对所述水溶性果胶凝胶体进行粗提，所述阳离子交换树脂例如是磺酸基或DEAE基阳离子交换树脂；和
步骤5：移除高分子量杂质，优选地使用截留分子量至少10 3-10 4Da之间的超滤膜移除高分子量杂质，例如所述超滤膜孔径为1-10nm，保持低压力差0.05-0.5MPa持续高流通萃取，截留分子量10 3-10 4Da。
2.根据技术方案1的方法，其中在实施步骤2之前对所述果皮进行酸处理，以获得稳定的水溶性果胶凝胶体；
优选地酸处理在pH值5-6下进行，优选地持续10-60分钟，例如10、15、20、30、40、45、50、60、75、90或120分钟。
3.根据技术方案1或2的方法，其中在步骤2碱处理时还进行微波加热，优选地加热至至少50℃，例如60、70、80、90或100℃。
4.根据技术方案1至3任一项的方法，其中在步骤2碱处理之前或之后还进行纤维素酶酶解处理；优选地添加1-10mg/g纤维素酶，酶解温度为环境温度至40℃，例如38℃，时间至少持续30分钟，例如持续30、40、45、50、60、70、75、80、90、100、120或150分钟。
5.根据技术方案1至4任一项的方法，其中所述果皮和/或果渣来自柑橘类、梨果类、葡萄类、葫芦科、芭蕉科水果或葵花盘，例如橘、柑、橙、金柑，柠檬、柚、枳金桔、苹果、梨、枇杷、山楂、杏、李、梅子、桃、猕猴桃、香蕉、葡萄、西瓜、向日葵。
6.根据技术方案1至5任一项的方法，其中对步骤4粗提产物进行酶解或发酵处理，如果粗提产物中低聚半乳糖醛酸含量为至少70％，则 对粗提产物进行酶法降解处理；如果粗提产物中低聚半乳糖醛酸含量低于70％，则对粗提产物进行酵母发酵处理；其中
所述酶法降解处理包括：调整果胶终浓度2-5wt％,在pH4.5进行等电点脱蛋白，然后向脱蛋白产物加入固态化果胶酶：裂解酶(PL，酶活度32U/g)，特异性内切聚半乳糖醛酸酶(Endo-polygalacturonases，endo-PG，E.C.3.2.1.15，4212U/g)，果胶酯酶(PE，E.C.3.1.1.11，66.7U/g)和原果胶酶，pH控制在3.0-6.0，持续时间至少30分钟，例如30、40、45、50、60、70、75、80、90、100、110、120分钟或更长时间，优选地温度至少37或更，例如40、42、45、50、55或60℃；以及
所述酵母发酵处理：调整果胶终浓度为2-5wt％，加入1-5wt％的活化的酿酒酵母(Saccharomyces cerevisiae)；优选地发酵温度为环境温度至35优选，例如30℃，优选地发酵持续至少12小时，例如12、18、24、36、48小时或更长时间。
7.根据技术方案1至6任一项的方法，其中碱性pH各自独立地使用强碱来实现，所述强碱例如选自NaOH、KOH或CaOH或其混合物，和/或酸性pH各自独立地使用稀酸来实现，所述稀酸例如选自盐酸、硫酸、磷酸、硝酸、亚硫酸、乙酸或其混合物。
8.根据技术方案1至7任一项的方法，其中所得低聚半乳糖醛酸多糖中半乳糖醛酸含量为至少90％如93-98％，酯化度例如为12-14％，和/或所述低聚半乳糖醛酸多糖的分子量为3kDa至8kDa。
9.一种可食用组合物，其包含技术方案1-8任一项所述的低聚半乳糖醛酸多糖；
优选地其包含或由以下组分制成：
如技术方案1-8任一项所述的低聚半乳糖醛酸多糖610-710重量份；以及
黄芪25-35重量份、炒山楂5-25重量份、红枣5-25重量份和陈皮6-20重量份。
10.一种制备技术方案9所述组合物的方法，其包括以下步骤：
将黄芪、炒山楂、红枣和陈皮经预处理后用水浸泡，然后煎煮至少15分钟，例如15、20、25、30、40、45、50、60、70、75、80、 90、100、120分钟或更长时间，过滤制备得到浸膏；和
将所述浸膏和低聚半乳糖醛酸多糖混合，得到所述可食用组合物。
11.根据技术方案10所述的方法，其中，所述浸泡的固液体积比为1：5-15，浸泡时间为20-60min。
12.技术方案1至8任一项方法制得的低聚半乳糖醛酸多糖、技术方案9所述的可食用组合物，用于治疗慢性炎症相关疾病，优选地以药品、食品或保健品的形式。
作为说明，本发明还提供了以下技术方案：
1.一种低聚半乳糖醛酸多糖的制备方法，其特征在于，包括以下步骤：
第一步，对橙子果皮预处理，得到稳定水溶性果胶凝胶体；以及
第二步，碱水解-微波法处理，在控制pH在12.0-13.0，微波加热至80-1003条件下，向所述稳定水溶性果胶凝胶体中加入氢氧化钠，形成断键水溶性果胶凝胶体；
第三步，脱甲氧基处理，对所述断键水溶性果胶凝胶体进行去甲氧基化处理，得到粗品脱甲氧基水溶性果胶凝胶体；
第四步，超滤膜精制，使用超滤膜进行精细提取，所述超滤膜孔径为1-10nm，保持低压力差0.05-0.5MPa持续高流通萃取，截留分子量在10 3-10 4。
2.根据技术方案1所述的低聚半乳糖醛酸多糖的制备方法，其特征在于，
在第三步中，所述脱甲氧基处理具体为：冷冻干燥浓缩，调整粗果胶浓度为10-20g/L，加入NaOH，维持pH在9-10，于4℃反应8-48h进行去甲酯化，最后用10％冰醋酸，调整酸度，终止反应；
第三步之后，对所述粗品脱甲氧基水溶性果胶凝胶体进行粗提处理，经过粗提处理后，低聚半乳糖醛酸多糖含量超过70％则进行酶解法降解处理；不超过70％的则进行酵母发酵法处理；
第四步之后，还包括减压旋转蒸发浓缩，低温干燥处理。
3.根据技术方案2所述的低聚半乳糖醛酸多糖的制备方法，其特征 在于，
所述酶解法降解处理：先使用等电点法脱蛋白，醋酸缓冲液调整pH值为4.5，调整果胶终浓度为2-5wt％；加入固态化果胶酶：裂解酶(PL，酶活度32U/g)，特异性内切聚半乳糖醛酸(Endo-polygalacturonases，endo-PG，E.C.3.2.1.15，4212U/g)，果胶酯酶(PE，E.C.3.1.1.11，66.7U/g)和原果胶酶，pH控制在3.0-6.0，45℃(最高不超过60℃)维持60-90分钟；
所述酵母发酵法处理：将酿酒活性干酵母加入2wt％蔗糖溶液，搅拌均匀，25-30℃放置2-4小时，使其活化；在2-5wt％浓度的果胶水溶液中，加入1-5wt％的活化好的酵母，30℃，发酵24-48小时。
4.根据技术方案1-3任一项所述的低聚半乳糖醛酸多糖的制备方法，其特征在于，所述低聚半乳糖醛酸多糖中半乳糖醛酸含量为93-98％，酯化度为12-14％。
5.低聚半乳糖醛酸多糖复合物，其特征在于，以重量份数计，包含：
如技术方案1-4任一项所述的低聚半乳糖醛酸多糖610-710重量份；以及
黄芪25-35重量份、炒山楂5-25重量份、红枣5-25重量份和陈皮6-20重量份；
所述低聚半乳糖醛酸多糖的分子量为3kDa至8kDa。
6.技术方案5所述的低聚半乳糖醛酸多糖复合物的制备方法，其特征在于，包括以下步骤：
将黄芪、炒山楂、红枣和陈皮经预处理后用水浸泡，然后煎煮30-60min、过滤制备得到浸膏；
将所述浸膏和低聚半乳糖醛酸多糖混合，得到低聚半乳糖醛酸多糖复合物。
7.根据技术方案6所述的制备方法，其特征在于，所述预处理包括依次进行的清洗、超声粉碎和过筛。
8.根据技术方案6所述的制备方法，其特征在于，所述浸泡的固液体积比为1：5-15，浸泡时间为20-60min。
9.根据技术方案6所述的制备方法，其特征在于，所述煎煮的时间为30-90min。
10.技术方案5所述的低聚半乳糖醛酸多糖复合物，以及技术方案6-9任一项所述方法制备得到的低聚半乳糖醛酸多糖复合物在制备治疗慢性炎症相关疾病的药品、食品或保健品中的应用。
附图说明
附图示出了本发明的示例性实施方式，并与其说明一起用于解释本发明的原理，其中包括了这些附图以提供对本发明的进一步理解，并且附图包括在本说明书中并构成本说明书的一部分。
图1为示出了在体外实验中，低聚半乳糖醛酸多糖复合物对小鼠成纤维细胞生长无毒害作用；
图2为示出了台盼蓝染色定性分析4T1细胞形成集落对比照片；
图3为示出了在小鼠乳腺癌4T1移植瘤化疗治疗模型实验中，MDSC细胞比例对比图；
图4为示出了在小鼠乳腺癌4T1移植瘤化疗治疗模型实验中，免疫抑制性细胞MDSC和Treg细胞水平对比图；
图5为示出了在小鼠乳腺癌4T1移植瘤化疗治疗模型实验中，免疫增强细胞Th1、Th17和CD8 +杀伤性T细胞水平对比图；
图6为示出了在小鼠乳腺癌4T1移植瘤化疗治疗模型实验中，中性粒细胞比例对比图；
图7为示出了小鼠LPS诱导慢性炎症实验中，小鼠体重曲线对比图；
图8为示出了小鼠LPS诱导慢性炎症实验中，免疫抑制性细胞MDSC和Treg细胞水平对比图；
图9为示出了小鼠LPS诱导慢性炎症实验中，免疫增强细胞Th1、Th17和CD8 +杀伤性T细胞水平对比图。
具体实施方式
下面结合附图和实施方式对本发明作进一步的详细说明。可以理解的是，此处所描述的具体实施方式仅用于解释相关内容，而非对本发明 的限定。另外还需要说明的是，为了便于描述，附图中仅示出了与本发明相关的部分。
需要说明的是，在不冲突的情况下，本发明中的实施方式及实施方式中的特征可以相互组合。下面将参考附图并结合实施方式来详细说明本发明。
实施例1
制备低聚半乳糖醛酸多糖：
(1)将橙子果皮漂洗，煮沸脱色，石油醚脱脂2次，可提供柑橘精油、柚苷等副产品；超声波粉碎，高效破坏果皮细胞壁结构，促进后续步骤粗果胶多糖释放；
(2)酸化预处理：用稀盐酸或亚硫酸溶解破碎的果皮，控制pH值在5.0-6.0，30min，形成稳定水溶性果胶凝胶体，过滤除渣；
(3)酶解：加入6mg/g的纤维素酶,维持温度38℃,酶解时间70min；
(4)碱水解-微波法：密闭培养罐中，向粗果胶凝胶水溶液，加入等量4mol/L NaOH,控制pH在12.0-13.0，微波加热至80-100°0，微波能量能引起水分子共振，提前进行长链多糖的共价键打断，缩短后续酶解或微生物发酵工序时长和原料消耗，搅拌40-120min，迅速冷却至室温；
(5)脱甲氧基：冷冻干燥浓缩，调整粗果胶浓度为10-20g/L，加入NaOH，维持pH在9-10，于4℃反应8-48h进行去甲酯化，最后用10％冰醋酸，调整酸度，终止反应；
(6)对粗制果胶，执行严格质控流程，用“DEAE-Sepharose ff离子交换柱+SephadexG50凝胶层析柱法”进行粗提，再用HPLC法，或者MALLS-HPGPC法测定所得HG分子量和酯化度；
(7)若粗果胶制品分子量均一，化学性质稳定，HG粗含量已达70％以上，后续可使用酶解法降解；HG粗含量未达70％，进入酵母发酵法；
(8)酶法降解：先使用等电点法脱蛋白，醋酸缓冲液调整pH值为4.5，调整果胶终浓度为2-5％。加入固态化果胶酶：裂解酶(PL，酶活度32U/g)，特异性内切聚半乳糖醛酸酶(Endo-polygalacturonases，endo-PG，E.C.3.2.1.15，4212U/g)，果胶酯酶(PE，E.C.3.1.1.11，66.7U/g)和原果胶酶，pH控制在3.0-6.0，45°5(最高不超过60°0)维持60-90分钟；
(9)HG粗含量未达70％，无需预先脱蛋白步骤，使用酿酒酵母(Saccharomycescerevisiae)发酵法，延长发酵降解时间：将酿酒活性干酵母加入2％蔗糖溶液，搅拌均匀，25-30°5放置2-4小时，使其活化；在2-5％浓度的果胶水溶液中，加入1-5％的活化好的酵母，30°0，发酵24-48小时；
(10)超滤膜精制：使用超滤膜进行精细提取，所述超滤膜孔径为1-10nm，保持低压力差0.05-0.5MPa持续高流通萃取，截留分子量在10 3-10 4；
(11)60-70°0减压旋转蒸发浓缩，低温干燥，得到分子量为8kDa的纯化低聚半乳糖醛酸多糖。
采用间羟基联苯比色法测定半乳糖醛酸含量，采用容量分析法测定酯化度。测得半乳糖醛酸含量为95％，酯化度为12％。
实施例2
制备低聚半乳糖醛酸多糖：
(1)将苹果果皮漂洗；
(2)碱水解：取果皮400g溶于2L水中，加入3mol/L NaOH 400ml,搅拌30min，冷却至室温；
(3)酶解：加入5mg/g的纤维素酶,维持温度38℃,酶解时间90min；
(4)HG粗含量未达70％，无需预先脱蛋白步骤，使用酿酒酵母(Saccharomycescerevisiae)发酵法，延长发酵降解时间：将酿酒活性干酵母加入2％蔗糖溶液，搅拌均匀，25-30°5放置2-4小时，使其活化；在2-5％浓度的果胶水溶液中，加入1-5％的活化好的酵母，30°0，发酵24-48小时；
(5)使用超滤膜进行精细提取，所述超滤膜孔径为1-10nm，保持低压力差0.05-0.5MPa持续高流通萃取，截留分子量在10 3-10 4；
(6)低温干燥，得到分子量为6kDa的纯化低聚半乳糖醛酸多糖。
采用间羟基联苯比色法测定半乳糖醛酸含量，采用容量分析法测定酯化度。测得半乳糖醛酸含量为93％，酯化度为14％。
实施例3
使用实施例1制得的低聚半乳糖醛酸多糖。
准备低聚半乳糖醛酸多糖625重量份、黄芪25重量份、炒山楂10重量份、红枣10重量份和陈皮8重量份。
将黄芪、炒山楂、红枣和陈皮经清洗、超声波粉碎、过筛，10倍双蒸水浸泡30分钟，小火煎1小时，过滤，制成浸膏；然后将该浸膏与低聚半乳糖醛酸多糖充分混合，制成粉剂。
对比例1
使用实施例1制得的低聚半乳糖醛酸多糖。
按照实施例3的方法制备低聚半乳糖醛酸多糖复合物，不加入炒山楂、红枣和陈皮。
实施例4
使用实施例1制得的低聚半乳糖醛酸多糖。准备低聚半乳糖醛酸多糖600重量份、黄芪35重量份、炒山楂10重量份、红枣20重量份和陈皮6重量份。
将黄芪、炒山楂、红枣和陈皮经清洗、超声波粉碎、过筛，5倍双蒸水浸泡40分钟，小火煎0.5小时，过滤除渣，制成浸膏；然后将该浸膏与低聚半乳糖醛酸多糖充分混合，制成片剂。
实施例5
使用实施例1制得的低聚半乳糖醛酸多糖。
准备低聚半乳糖醛酸多糖700重量份、黄芪20重量份、炒山楂20重量份、红枣10重量份和陈皮15重量份。
将黄芪、炒山楂、红枣和陈皮经清洗、超声波粉碎、过筛，10倍双蒸水浸泡60分钟，小火煎1.5小时，过滤除渣，制成浸膏；然后将该浸膏与低聚半乳糖醛酸多糖充分混合，制成胶囊。
实施例6无毒害作用
实施例3的低聚半乳糖醛酸多糖复合物(以下简称为HG+中药复合物)为按照最优比配置，含有低聚半乳糖醛酸多糖625重量份、黄芪25重量份、炒山楂10重量份、红枣10重量份和陈皮8重量份。
(1)在体外实验中，本申请的低聚半乳糖醛酸多糖复合物对小鼠成纤维细胞生长无明显毒害作用。
在96孔细胞培养板内无菌接种Balb/c小鼠尾部成纤维细胞1鼠尾部 5，每3孔接种浓度为10种浓度为维的低聚半乳糖醛酸多糖复合物的细胞完全培养液1640，其他3孔为加入20加入生理盐水的对照组，终体积均为0.2ml，每隔24小时终止细胞培养，用MTT法测定培养细胞活力。结果如图1所示。
(2)在体外实验中，本申请的低聚半乳糖醛酸多糖复合物对小鼠4T1乳腺癌细胞，无明显杀伤作用。
在6孔细胞培养板内无菌接种Balb/c小鼠4T1乳腺癌细胞，每孔接种1腺癌细 4个，加入2ml含不同浓度低聚半乳糖醛酸多糖复合物的细胞完全培养液1640，低聚半乳糖醛酸多糖复合物的浓度依次为0.01、0.1、1.0、10.0、100.0合物的浓度，对照组为20照组不含低聚半乳糖醛酸多糖复合物的生理盐水。48小时后终止细胞培养，用台盼蓝染色，定性分析4T1细胞形成集落的密度和大小，未见明显差异，结果如图2所示。
实施例7
取对数生长期鼠巨噬细胞RAW264.7，以5以W2 3个/8026完全DMEM培养基密度，接种于96孔培养板，设置空白组、对照组和不同浓度的样品组，每组设6个平行孔，于37°7，5％(v/v)CO 2培养箱中进行培养。培养过夜，待第二天细胞密度达50-60％，分别加入培养基和不同浓度的低聚半乳糖醛酸多糖复合物预处理8小时(实施例3的低聚半乳糖醛酸多糖复合物)。
空白对照组:只加入100照组完全DMEM培养基；
阳性对照组：每孔加入含LPS的完全培养基100培养，使LPS终浓度为500ng/ml；
处理组1:在培养基中加入100基中含有低聚半乳糖醛酸多糖复合物的完全DEME培养基，使低聚半乳糖醛酸多糖复合物终浓度为2酸多糖复合物
处理组2:在培养基中加入100基中含有低聚半乳糖醛酸多糖复合物的完全DEME培养基，使低聚半乳糖醛酸多糖复合物终浓度为4酸多糖复合物
处理组3:在培养基中加入100基中含有低聚半乳糖醛酸多糖复合物的完全DEME培养基，使低聚半乳糖醛酸多糖复合物终浓度为8酸多糖复合物
处理组4:在培养基中加入100基中含有低聚半乳糖醛酸多糖复合物的完全DEME培养基，使低聚半乳糖醛酸多糖复合物终浓度为16多糖复合物。
向处理组1-4每孔加入含LPS的完全培养基20全培，使LPS终浓度为500ng/ml，处理16小时，培养结束后，使用MTT法测定培养后的RAW264.7细胞的存活率。
读取酶标仪A550nm吸光值，以空白组平均值为相对细胞活力100％，计算每组细胞活力相对值(每组实验重复6次，所测结果取6组平均值)。
表1 LPS炎症模型中，低聚半乳糖醛酸多糖复合物不同浓度的细胞存活率
Figure PCTCN2022117713-appb-000002
实施例8
本申请的低聚半乳糖醛酸多糖复合物在体外具有拮抗慢性炎症相关的免疫抑制性细胞：MDSC和Treg细胞的增殖和分化的作用。
(1)低聚半乳糖醛酸多糖复合物口服，能明显减少荷瘤小鼠脾脏内MDSC细胞比例。
荷瘤小鼠口服低聚半乳糖醛酸多糖复合物实验终点时，提取小鼠脾脏细胞，进行流式分析，结果显示，处理组(5-FU+低聚半乳糖醛酸多糖复合物)能明显降低免疫抑制性细胞MDSC的比例。结果如图3所示。
(2)在体外培养，低聚半乳糖醛酸多糖复合物减少免疫抑制性细胞MDSC和Treg细胞的分化比例。
在48孔细胞培养板内培养荷瘤小鼠的脾脏细胞1细胞培 6，对照组加入每孔生理盐水20照组，处理组低聚半乳糖醛酸多糖复合物浓度为10糖醛酸多糖，终体积均为1ml，48小时后终止细胞培养，使用流式细胞仪检测IFN +Th1细胞、IL-17a +Th17细胞和CD8 +杀伤性T细胞比例，CD4 +CD25 hi抑制性Treg细胞比例，和CD11b +Gr-1 +抑制性MDSC细胞比例。结果如图4和图5所示。
(3)在体外培养，低聚半乳糖醛酸多糖复合物增加免疫正性效应细胞：Th1、Th17和CD8 +杀伤性T细胞分化比例，结果如图5所示。
实施例9低聚半乳糖醛酸多糖复合物具有升白细胞、减轻化疗血液学毒性的作用
在荷瘤小鼠的脾脏中，5-FU+低聚半乳糖醛酸多糖复合物处理组，中性粒细胞比例较5-FU化疗组增加，结果如图6所示。
实施例10小鼠LPS诱导慢性炎症实验
8-10周龄Balb/c雌性小鼠，随机分为5组,每组8只：
空白组：腹腔注射100：腹生理盐水；
阳性对照组及处理组：使用低剂量LPS腹腔注射(0.5mg/kg体重，50，m，3天一次)8次，第0天-第21天；
低聚半乳糖醛酸多糖治疗组：使用低剂量LPS腹腔注射(0.5mg/kg体重，50，m，3天一次)，第0天开始，每日口服低聚半乳糖醛酸多糖(实施例1)，口服量为2g/kg体重·天；
低聚半乳糖醛酸多糖+黄芪治疗组：使用低剂量LPS腹腔注射(0.5mg/kg体重，50，m，3天一次)，第0天开始，每日口服低聚半乳糖醛酸多糖+黄芪(对比例1)，口服量为2.03g/kg体重·天；
低聚半乳糖醛酸多糖复合物治疗组：使用低剂量LPS腹腔注射(0.5mg/kg体重，50，m，3天一次)，第0天开始，每日口服低聚半乳糖醛酸多糖复合物(实施例3)，口服量为2.17g/kg体重·天。
第22天(腹腔注射+口服药21天后)：
(1)空白组：小鼠精神正常，进食及饮水正常，未见明显异常摄食、运动、排泄行为；
(2)阳性对照组：小鼠精神差，萎靡不振，进食及饮水量减少，对刺激反应迟钝，倦怠懒动或易激惹，体重减轻明显，出现脱毛，小便未见明显异常，大便稀软，偶有糊状、粘液、脓血便。
(3)低聚半乳糖醛酸多糖治疗组(HG治疗组)：小鼠精神好转，进食及饮水量恢复至基本正常，体重缓慢增加，偶有毛发稀疏，小便未见明显异常，大便基本成型，偶有粘液便。
(4)低聚半乳糖醛酸多糖+黄芪治疗组(HG+黄芪治疗组):小鼠精神好转，进食及饮水量恢复至基本正常，体重正常缓慢增加，毛发稀疏不常见，小便未见明显异常，大便成型，偶有粘液便。
(5)低聚半乳糖醛酸多糖复合物治疗组(HG+中药复合物治疗组)：精神状态好，进食及饮水正常，动作灵敏、喜动，体重正常增加，毛色光亮，大便成形，椭圆形颗粒状，黄褐色，质地硬，无粘液、无脓血。
记录实验过程中，各组小鼠体重增长曲线，可见阳性对照组明显慢性炎症所致明显恶病质，和HG、HG+黄芪、HG+中药复合物的治疗效果。结果如图7所示。
小鼠LPS诱导慢性炎症实验终点，提取小鼠脾脏细胞，进行流式分析，结果显示，腹腔低浓度LPS长期处理，引起阳性对照组脾脏免 疫抑制性细胞：MDSC和Treg细胞明显升高；低聚半乳糖醛酸多糖和低聚半乳糖醛酸多糖+黄芪治疗组治疗，都能够降低由LPS处理引起的慢性炎症所导致的MDSC细胞和Treg细胞比例升高；低聚半乳糖醛酸多糖复合物治疗组，相比低聚半乳糖醛酸多糖组和低聚半乳糖醛酸多糖+黄芪治疗组能更明显降低LPS慢性炎症引起的免疫抑制性细胞MDSC和Treg细胞升高。结果如图8所示。
表2 LPS小鼠抗炎实验中，不同处理组的MDSC和Treg细胞比例。
Figure PCTCN2022117713-appb-000003
实施例11
小鼠LPS诱导慢性炎症实验终点，提取小鼠脾脏细胞，进行流式分析，使用流式细胞仪检测IFN +Th1细胞、IL-17a +Th17细胞和CD8 +杀伤性T细胞比例。结果如图9所示。
图9示出，低聚半乳糖醛酸多糖复合物增加免疫正性效应细胞Th1、Th17和CD8 +杀伤性T细胞分化比例。
表3LPS小鼠抗炎实验中，不同处理组中免疫正性效应细胞Th1、Th17和CD8+杀伤性T细胞分化比例。
Figure PCTCN2022117713-appb-000004
以上实验表明，本申请提供的低聚半乳糖醛酸多糖复合物，在体外实验中，对小鼠成纤维细胞没有明显杀伤作用，还能调节免疫细胞分化，具有降低CD4调节性T细胞比例、降低MDSC细胞的比例的作用。小鼠口服低聚半乳糖醛酸多糖后，能在体内拮抗MDSC细胞相关慢性炎症，能降低外周血CD4Treg细胞比例，升高CD8T细胞比例。能在体内拮抗小鼠4T1乳腺癌移植瘤化疗模型引起的白细胞下降，有明显的升白细胞功能，并能降低接种肿瘤部位的浸润淋巴细胞里的MDSC细胞比例，增加CD8T细胞比例。
特别地，在小鼠LPS诱导慢性炎症实验中，小鼠口服低聚半乳糖醛酸多糖复合物后，能在体内拮抗MDSC细胞相关慢性炎症，能降低外周血CD4Treg细胞比例，升高CD8T细胞比例。特别地，与低聚半乳糖醛酸多糖相比，本申请的低聚半乳糖醛酸多糖复合物具有良好的拮抗MDSC细胞相关慢性炎症，能降低外周血CD4Treg细胞比例，升高CD8T细胞比例的效果。
需要说明的是，本发明实施例对本发明上述方案均具有优选举例作用，只要属于本发明上述关于多糖的制备中的具体步骤或步骤组合，均涵盖本发明记载实施例和对比例的效果范围。
因此，本申请提供的低聚半乳糖醛酸多糖复合物具有增强免疫力、保肝护肝、抗慢性炎症、抗氧化应激、抗衰老的新功能，将其用于制备药品、食品或保健品，该药品、食品或保健品可用于MDSC相关慢性炎症的治疗价值，兼具升白细胞、减轻化疗血液学毒性的治疗价值。
在本说明书的描述中，参考术语“一个实施例/方式”、“一些实施例/方式”、“示例”、“具体示例”、或“一些示例”等的描述意指结合该实施例/方式或示例描述的具体特征、结构、材料或者特点包含于本申请的至少一个实施例/方式或示例中。在本说明书中，对上述术语的示意性表述不必须针对的是相同的实施例/方式或示例。而且，描述的具体特征、结构、材料或者特点可以在任一个或多个实施例/方式或示例中以合适的方式结合。此外，在不相互矛盾的情况下，本领域的技术人员可以将本说明书中描述的不同实施例/方式或示例以及不同实施例/方式或示例的特征进行结合和组合。
此外，术语“第一”、“第二”仅用于描述目的，而不能理解为指示或暗示相对重要性或者隐含指明所指示的技术特征的数量。由此，限定有“第一”、“第二”的特征可以明示或者隐含地包括至少一个该特征。在本申请的描述中，“多个”的含义是至少两个，例如两个，三个等，除非另有明确具体的限定。
本领域的技术人员应当理解，上述实施方式仅仅是为了清楚地说明本发明，而并非是对本发明的范围进行限定。对于所属领域的技术人员而言，在上述公开的基础上还可以做出其它变化或变型，并且这些变化或变型仍处于本发明的范围内。

Claims (12)

  1. 一种制备低聚半乳糖醛酸多糖的方法，包括以下步骤：
    步骤1：提供含果胶的果皮和/或果渣；
    步骤2：使步骤1获得的原料与碱性水溶液接触以进行碱处理，保持混合物pH值不低于11，以获得断键水溶性果胶凝胶体；优选地碱处理pH值为12-13，优选地持续至少30分钟，例如30、40、50、60、70、80、90、100、110或120分钟；
    步骤3：任选地将步骤2获得的断键水溶性果胶凝胶体浓缩，在pH9-11、温度0-8℃下持续至少2小时，然后调节pH至接近中性如6-8，对所述断键水溶性果胶凝胶体进行去甲氧基化处理，得到粗品脱甲氧基水溶性果胶凝胶体；；优选地使用冷冻干燥进行浓缩；优选地浓缩至粗果胶浓度至少5g/L，例如10、15、20、25、30或40g/L，具体地如10-20g/L；优选地pH值为9-10，优选地持续2、3、4、5、6、7、8、9、10、12、15、18、20、24、30、36、40、48、60、72小时或更长时间；
    步骤4：任选地使用阳离子交换树脂对所述水溶性果胶凝胶体进行粗提，所述阳离子交换树脂例如是磺酸基或DEAE基阳离子交换树脂；和
    步骤5：移除高分子量杂质，优选地使用截留分子量至少10 3-10 4Da之间的超滤膜移除高分子量杂质，例如所述超滤膜孔径为1-10nm，保持低压力差0.05-0.5MPa持续高流通萃取，截留分子量10 3-10 4Da。
  2. 根据权利要求1的方法，其中在实施步骤2之前对所述果皮进行酸处理，以获得稳定的水溶性果胶凝胶体；
    优选地酸处理在pH值5-6下进行，优选地持续10-60分钟，例如10、15、20、30、40、45、50、60、75、90或120分钟。
  3. 根据权利要求1或2的方法，其中在步骤2碱处理时还进行微波加热，优选地加热至至少50℃，例如60、70、80、90或100℃。
  4. 根据权利要求1至3任一项的方法，其中在步骤2碱处理之前或之后还进行纤维素酶酶解处理；优选地添加1-10mg/g纤维素酶，酶解温度为环境温度至40℃，例如38℃，时间至少持续30分钟，例如持续30、40、45、50、60、70、75、80、90、100、120或150分钟。
  5. 根据权利要求1至4任一项的方法，其中所述果皮和/或果渣来自 柑橘类、梨果类、葡萄类、葫芦科、芭蕉科水果或葵花盘，例如橘、柑、橙、金柑，柠檬、柚、枳金桔、苹果、梨、枇杷、山楂、杏、李、梅子、桃、猕猴桃、香蕉、葡萄、西瓜、向日葵。
  6. 根据权利要求1至5任一项的方法，其中对步骤4粗提产物进行酶解或发酵处理，如果粗提产物中低聚半乳糖醛酸含量为至少70％，则对粗提产物进行酶法降解处理；如果粗提产物中低聚半乳糖醛酸含量低于70％，则对粗提产物进行酵母发酵处理；其中
    所述酶法降解处理包括：调整果胶终浓度2-5wt％,在pH4.5进行等电点脱蛋白，然后向脱蛋白产物加入固态化果胶酶：裂解酶(PL，酶活度32U/g)，特异性内切聚半乳糖醛酸酶(Endo-polygalacturonases，endo-PG，E.C.3.2.1.15，4212U/g)，果胶酯酶(PE，E.C.3.1.1.11，66.7U/g)和原果胶酶，pH控制在3.0-6.0，持续时间至少30分钟，例如30、40、45、50、60、70、75、80、90、100、110、120分钟或更长时间，优选地温度至少37或更，例如40、42、45、50、55或60°0；以及
    所述酵母发酵处理：调整果胶终浓度为2-5wt％，加入1-5wt％的活化的酿酒酵母(Saccharomyces cerevisiae)；优选地发酵温度为环境温度至35温度，例如30°0，优选地发酵持续至少12小时，例如12、18、24、36、48小时或更长时间。
  7. 根据权利要求1至6任一项的方法，其中碱性pH各自独立地使用强碱来实现，所述强碱例如选自NaOH、KOH或CaOH或其混合物，和/或酸性pH各自独立地使用稀酸来实现，所述稀酸例如选自盐酸、硫酸、磷酸、硝酸、亚硫酸、乙酸或其混合物。
  8. 根据权利要求1至7任一项的方法，其中所得低聚半乳糖醛酸多糖中半乳糖醛酸含量为至少90％如93-98％，酯化度例如为12-14％，和/或所述低聚半乳糖醛酸多糖的分子量为3kDa至8kDa。
  9. 一种可食用组合物，其包含权利要求1-8任一项所述的低聚半乳糖醛酸多糖；
    优选地其包含或由以下组分制成：
    如权利要求1-8任一项所述的低聚半乳糖醛酸多糖610-710重量份；以及
    黄芪25-35重量份、炒山楂5-25重量份、红枣5-25重量份和陈皮6-20重量份。
  10. 一种制备权利要求9所述组合物的方法，其包括以下步骤：
    将黄芪、炒山楂、红枣和陈皮经预处理后用水浸泡，然后煎煮至少15分钟，例如15、20、25、30、40、45、50、60、70、75、80、90、100、120分钟或更长时间，过滤制备得到浸膏；和
    将所述浸膏和低聚半乳糖醛酸多糖混合，得到所述可食用组合物。
  11. 根据权利要求10所述的方法，其中，所述浸泡的固液体积比为1：5-15，浸泡时间为20-60min。
  12. 权利要求1至8任一项方法制得的低聚半乳糖醛酸多糖、权利要求9所述的可食用组合物，用于治疗慢性炎症相关疾病，优选地以药品、食品或保健品的形式。
PCT/CN2022/117713 2021-09-08 2022-09-08 低聚半乳糖醛酸多糖、复合物及其制备方法和应用 WO2023036219A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023544454A JP2024505861A (ja) 2021-09-08 2022-09-08 オリゴガラクツロン酸多糖、複合体及びその調製方法並びにその使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111050134.0A CN113480676B (zh) 2021-09-08 2021-09-08 低聚半乳糖醛酸多糖、复合物及其制备方法和应用
CN202111050134.0 2021-09-08

Publications (1)

Publication Number Publication Date
WO2023036219A1 true WO2023036219A1 (zh) 2023-03-16

Family

ID=77946756

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/117713 WO2023036219A1 (zh) 2021-09-08 2022-09-08 低聚半乳糖醛酸多糖、复合物及其制备方法和应用

Country Status (3)

Country Link
JP (1) JP2024505861A (zh)
CN (1) CN113480676B (zh)
WO (1) WO2023036219A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117512032A (zh) * 2023-11-07 2024-02-06 北京市农林科学院 低分子量hg型果胶的制备方法及其构象表征

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113480676B (zh) * 2021-09-08 2021-12-03 天津银杉科技有限公司 低聚半乳糖醛酸多糖、复合物及其制备方法和应用
CN114592019B (zh) * 2022-04-06 2023-08-15 厦门爱逸零食研究所有限公司 圆苞车前子多糖联合制备寡糖的方法及其应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101642275A (zh) * 2009-03-26 2010-02-10 王可剑 一种滋补、防病、治病的药剂饮料
CN104593450A (zh) * 2015-01-26 2015-05-06 湖北大学 一种利用果胶酶裂解高酯化度果胶制备单糖和低聚半乳糖醛酸的方法
CN105647993A (zh) * 2016-02-24 2016-06-08 安徽宇宁生物科技有限公司 一种液态低聚半乳糖醛酸果胶生产工艺
CN110652013A (zh) * 2019-09-25 2020-01-07 中国农业科学院农产品加工研究所 一种高效制备具有缓解ⅱ型糖尿病的柑橘果胶的方法
CN110951804A (zh) * 2019-12-06 2020-04-03 中国农业科学院农产品加工研究所 提高肠道菌群多样性的苹果果胶杂多糖及其制备方法
FR3087440A1 (fr) * 2018-10-22 2020-04-24 Universite De Bourgogne Composes polysaccharidiques, et leur utilisation pour stimuler des reponses de defense des plantes contre les microorganismes pathogenes
CN112266941A (zh) * 2020-09-30 2021-01-26 浙江果源康品生物科技有限公司 酶碱结合生产小分子果胶的方法
CN113480676A (zh) * 2021-09-08 2021-10-08 天津银杉科技有限公司 低聚半乳糖醛酸多糖、复合物及其制备方法和应用
CN113633689A (zh) * 2021-09-08 2021-11-12 天津银杉科技有限公司 低聚半乳糖醛酸聚糖中药复合制剂、制备方法及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103833870B (zh) * 2014-03-03 2016-06-01 河南科技大学 一种从苹果渣中提取低甲氧基果胶的方法
CN104873533A (zh) * 2015-04-29 2015-09-02 浙江大学 小分子柑橘果胶的用途
CN105968228A (zh) * 2016-07-02 2016-09-28 郭迎庆 一种低甲氧基果胶的制备方法
CN106632724B (zh) * 2016-12-23 2019-03-05 浙江大学 一种高效制备低分子量果胶的方法
CN107141369B (zh) * 2017-05-25 2019-10-18 华南理工大学 一种改性果胶的制备方法
CN107266608A (zh) * 2017-07-25 2017-10-20 孔科喜 柑橘皮果胶的提取方法
CN109811021A (zh) * 2017-11-20 2019-05-28 中国科学院大连化学物理研究所 一种低分子果胶的制备方法
CN108641012A (zh) * 2018-03-12 2018-10-12 湖北大学知行学院 一种以野生皱皮柑为原料提取果胶的方法
CN111217935A (zh) * 2018-11-25 2020-06-02 中国科学院大连化学物理研究所 一种小分子柑橘果胶及制备方法

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101642275A (zh) * 2009-03-26 2010-02-10 王可剑 一种滋补、防病、治病的药剂饮料
CN104593450A (zh) * 2015-01-26 2015-05-06 湖北大学 一种利用果胶酶裂解高酯化度果胶制备单糖和低聚半乳糖醛酸的方法
CN105647993A (zh) * 2016-02-24 2016-06-08 安徽宇宁生物科技有限公司 一种液态低聚半乳糖醛酸果胶生产工艺
FR3087440A1 (fr) * 2018-10-22 2020-04-24 Universite De Bourgogne Composes polysaccharidiques, et leur utilisation pour stimuler des reponses de defense des plantes contre les microorganismes pathogenes
CN110652013A (zh) * 2019-09-25 2020-01-07 中国农业科学院农产品加工研究所 一种高效制备具有缓解ⅱ型糖尿病的柑橘果胶的方法
CN110951804A (zh) * 2019-12-06 2020-04-03 中国农业科学院农产品加工研究所 提高肠道菌群多样性的苹果果胶杂多糖及其制备方法
CN112266941A (zh) * 2020-09-30 2021-01-26 浙江果源康品生物科技有限公司 酶碱结合生产小分子果胶的方法
CN113480676A (zh) * 2021-09-08 2021-10-08 天津银杉科技有限公司 低聚半乳糖醛酸多糖、复合物及其制备方法和应用
CN113633689A (zh) * 2021-09-08 2021-11-12 天津银杉科技有限公司 低聚半乳糖醛酸聚糖中药复合制剂、制备方法及应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Doctoral Dissertation", 1 May 2014, ZHEJIANG UNIVERSITY, CN, article SHEN, YANWEI: "The Synergistic Effect of Low Molecular Weight Citrus Pectin on Chemotherapy in Murine Breast Cancer Model through Inhibition of MDSC Related Galectin-3", pages: 1 - 67, XP009544389 *
"Doctoral Dissertation", 15 August 2011, NORTHWEST UNIVERSITY, CN, article LI, JIANJUN: "The Study on the Controlled Degradation of Citrus Pectic Polysaccharide and the Purification and Activity of Oligogalacturonic Acid Fragments", pages: 1 - 106, XP009544388 *
"Master's Thesis", 1 June 2016, JIANGNAN UNIVERSITY, CN, article CHEN, YING: "Preparation of Modified Pectin and the Structure Characteristics of Its Binding to GAL-3", pages: 1 - 65, XP009544387 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117512032A (zh) * 2023-11-07 2024-02-06 北京市农林科学院 低分子量hg型果胶的制备方法及其构象表征
CN117512032B (zh) * 2023-11-07 2024-04-30 北京市农林科学院 低分子量hg型果胶的制备方法及其构象表征

Also Published As

Publication number Publication date
CN113480676B (zh) 2021-12-03
JP2024505861A (ja) 2024-02-08
CN113480676A (zh) 2021-10-08

Similar Documents

Publication Publication Date Title
WO2023036219A1 (zh) 低聚半乳糖醛酸多糖、复合物及其制备方法和应用
Mirzadeh et al. Plant/algal polysaccharides extracted by microwave: A review on hypoglycemic, hypolipidemic, prebiotic, and immune-stimulatory effect
EP1902722B1 (en) Agent for elevating adiponectin concentration
AU679262B2 (en) Blocking the accumulation of germs on human cells
Zeng et al. Recent research advances in polysaccharides from Undaria pinnatifida: Isolation, structures, bioactivities, and applications
CN101496581B (zh) 一种调节血脂的保健食品
KR102495397B1 (ko) 당 확산 추출공법으로 추출한 생병풀 추출물을 포함하는 항염, 장벽 효능을 가지는 화장료 조성물 및 이의 용도
CN101069562A (zh) 一种以枸杞酒渣为原料制备高免疫调节活性枸杞多糖的酶解工艺
CN114774493A (zh) 一种桑黄活性物质多糖的提取及纯化方法
JP4484014B2 (ja) ヒアルロニダーゼ阻害、抗アレルギー活性および免疫賦活物質
US20190249211A1 (en) Method for preparing high productivity mushroom beta-glucan and products thereof
CN116425897B (zh) 刺梨多糖、其制备方法及应用
CN111909285A (zh) 一种黑木耳多糖及其应用和制备方法
CN112691115A (zh) 预防/治疗胃肠粘膜和肝脏损伤的阿拉伯木聚糖及复合物
EP1768682B1 (en) Product of vegetal origin comprising proanthocyanidines and its preparation process
CN113633689A (zh) 低聚半乳糖醛酸聚糖中药复合制剂、制备方法及应用
CN107459586B (zh) 一种大腹皮多糖及低聚糖的制备方法及应用
JPH06247861A (ja) 抗潰瘍剤およびその製造法
Lin et al. Extraction, structure and bioactivities of polysaccharides from Sanghuangporus spp.: A review
CN115010823A (zh) 一种调节肠道菌群的车前子多糖及其制备方法与应用
KR102290859B1 (ko) 사포닌과 고순도의 산성다당체를 함유하는 홍삼 추출물, 그 제조방법 및 이를 포함하는 건강기능성 식품
Qian et al. Physical-chemical properties of heteropolysaccharides from different processed forms of Rehmanniae Radix
JP2005068114A (ja) タモギタケ子実体組成物及びその製造方法、並びに免疫賦活剤、抗癌剤及び食品製剤
CN109432349B (zh) 真菌共生发酵抗肿瘤姜黄及其制备方法
JPS6118722A (ja) 生体防御能亢進剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22866682

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2023544454

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE